Immunocore Holdings plc Cost Of Sales
Immunocore Holdings plc (IMCR) reported Cost Of Sales of GBP 886.00 thousand for the 3-month period ending 2023-06-30, per its 6-K filed 2023-08-10.
Discontinued › Expense Statement
ifrs-full:CostOfSales · last filed 2023-08-10
- Immunocore Holdings plc cost of sales for the quarter ending 2023-06-30 was 886.00K GBP, a 2505.88% increase year-over-year.
- Immunocore Holdings plc cost of sales for the quarter ending 2022-12-31 was 109.00K GBP.
- Immunocore Holdings plc cost of sales for the quarter ending 2022-09-30 was 63.00K GBP.
- Immunocore Holdings plc cost of sales for the quarter ending 2022-06-30 was 34.00K GBP.
| Period end | Cost Of Sales 3 month | Cost Of Sales 6 month | Cost Of Sales 9 month | Cost Of Sales 12 month |
|---|---|---|---|---|
| 2023-06-30 | 886.00K GBP 6-K · filed 2023-08-10 | 1.06M GBP 6-K · filed 2023-08-10 | ||
| 2022-12-31 | 109.00K GBP derived: 20-F 12 month − 6-K/A 9 month · filed 2023-03-01 | 172.00K GBP derived: sum of 2 quarters · filed 2023-03-01 | 206.00K GBP derived: sum of 3 quarters · filed 2023-08-10 | 454.00K GBP 20-F · filed 2023-03-01 |
| 2022-09-30 | 63.00K GBP 6-K/A · filed 2022-11-18 | 97.00K GBP derived: sum of 2 quarters · filed 2023-08-10 | 345.00K GBP 6-K/A · filed 2022-11-18 | |
| 2022-06-30 | 34.00K GBP 6-K · filed 2023-08-10 | 282.00K GBP 6-K · filed 2023-08-10 | ||
| 2021-12-31 | 0.00 GBP derived: 20-F 12 month − 6-K/A 9 month · filed 2023-03-01 | 0.00 GBP derived: sum of 2 quarters · filed 2023-03-01 | 0.00 GBP 20-F · filed 2023-03-01 | |
| 2021-09-30 | 0.00 GBP 6-K/A · filed 2022-11-18 | 0.00 GBP 6-K/A · filed 2022-11-18 | ||
| 2020-12-31 | 0.00 GBP 20-F · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |